2020 VISION: TRENDS & TECHNOLOGIES OF TOMORROW

Introducing flexibility to automation to unleash the power of biology – Podcast

Cell & Gene Therapy Insights 2019; 5(12), 1691–1696.

10.18609/cgti.2019.177

Published: 10 February 2020
Podcast
Markus Gershater


Markus Gershater co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering. Prior to UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Markus has a PhD in Plant Biochemistry from Durham.


Full podcast





Podcast questions








Authorship & Conflict of Interest

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Acknowledgements: None.
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest.
Funding declaration:The author received no financial support for the research, authorship and/or publication of this article. 

Article & copyright information

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
Attribution: Copyright © 2019 Markus Gershater. Published by Cell and Gene Therapy Insights
under Creative Commons License Deed CC BY NC ND 4.0.
Article source: Invited
Interview conducted: November 29 2019; Publication date: January 22 2020.

Affiliations

Markus Gershater
Chief Scientific Officer,
Synthace


This article is part of the 2020 Vision: Trends & Technologies of Tomorrow spotlight